We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+11.25%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$23.8B
AUM Growth
+$2.95B
Cap. Flow
+$1.1B
Cap. Flow %
4.63%
Top 10 Hldgs %
44.66%
Holding
165
New
18
Increased
38
Reduced
31
Closed
20

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$3.14B
2
AMZN icon
Amazon
AMZN
+$601M
3
AON icon
Aon
AON
+$226M
4
TMO icon
Thermo Fisher Scientific
TMO
+$145M
5
AZEK
The AZEK Co
AZEK
+$100M

Top Sells

Rank Stock Value
1
DFS
Discover Financial Services
DFS
+$816M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$403M
3
EXEL icon
Exelixis
EXEL
+$260M
4
MSFT icon
Microsoft
MSFT
+$234M
5
INTU icon
Intuit
INTU
+$205M

Sector Composition

Rank Sector Weight
1 Healthcare 32.61%
2 Technology 13.02%
3 Financials 8.98%
4 Communication Services 7.2%
5 Industrials 5.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COR icon
101
Cencora
COR
$60.7B
$300K ﹤0.01%
1,000
– –
UTHR icon
102
United Therapeutics
UTHR
$22B
$287K ﹤0.01%
1,000
– –
TWST icon
103
Twist Bioscience
TWST
$9.13B
$281K ﹤0.01%
7,650
– –
MMSI icon
104
Merit Medical Systems
MMSI
$5.42B
$280K ﹤0.01%
3,000
– –
KRYS icon
105
Krystal Biotech
KRYS
$10.3B
$275K ﹤0.01%
2,000
– –
LIVN icon
106
LivaNova
LIVN
$4.34B
$270K ﹤0.01%
6,000
-31,000
-84% -$1.28M
GKOS icon
107
Glaukos
GKOS
$10.9B
$269K ﹤0.01%
2,600
– –
ONC
108
BeOne Medicines Ltd
ONC
$42.4B
$266K ﹤0.01%
1,100
– –
ACLX
109
DELISTED
Arcellx
ACLX
$263K ﹤0.01%
4,000
– –
SBRA icon
110
Sabra Healthcare REIT
SBRA
$5.21B
$258K ﹤0.01%
14,000
– –
GRFS
111
Grifois
GRFS
$5.44B
$253K ﹤0.01%
28,000
– –
ARWR icon
112
Arrowhead Research
ARWR
$12.3B
$250K ﹤0.01%
15,800
– –
SRRK icon
113
Scholar Rock
SRRK
$6.88B
$248K ﹤0.01%
7,000
– –
ASND icon
114
Ascendis Pharma A/S
ASND
$16.6B
$242K ﹤0.01%
1,400
– –
SWTX
115
DELISTED
SpringWorks Therapeutics
SWTX
$235K ﹤0.01%
5,000
-113,000
-96% -$5.03M
ANNAW
116
AleAnna Inc Warrant
ANNAW
$7.3M
$233K ﹤0.01%
990,000
– –
AKRO
117
DELISTED
Akero Therapeutics
AKRO
$213K ﹤0.01%
+4,000
New +$182K
CGON icon
118
CG Oncology
CGON
$7.07B
$208K ﹤0.01%
+8,000
New +$193K
BRKR icon
119
Bruker
BRKR
$9.07B
$206K ﹤0.01%
5,000
– –
QURE icon
120
uniQure
QURE
$3.36B
$195K ﹤0.01%
14,000
– –
IMVT icon
121
Immunovant
IMVT
$9.16B
$192K ﹤0.01%
12,000
– –
HR icon
122
Healthcare Realty
HR
$6.65B
$190K ﹤0.01%
12,000
– –
TVTX icon
123
Travere Therapeutics
TVTX
$6.19B
$178K ﹤0.01%
+12,000
New +$199K
PACB icon
124
Pacific Biosciences
PACB
$420M
$167K ﹤0.01%
135,000
– –
EVH icon
125
Evolent Health
EVH
$536M
$158K ﹤0.01%
14,000
– –
3 4
5
6 7

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q2 2025 Portfolio in Review

As of Q2 2025, Thomas Steyer held 165 positions worth $23.8B, up 14% from $20.9B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Thomas Steyer deployed $1.1B of net new capital in Q2 2025, opening 18 new positions and adding to 38 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 5,500,000 shares worth $3.4B.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 38% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Exelixis, an estimated $260M trimmed.

  • Thomas Steyer's largest Q2 2025 buy was State Street SPDR S&P 500 ETF Trust: 5,500,000 shares worth $3.4B.
  • Thomas Steyer added most to Aon in Q2 2025, an estimated $226M increase.
  • Thomas Steyer's biggest Q2 2025 reduction was Exelixis, cutting an estimated $260M.
  • Thomas Steyer fully exited Discover Financial Services in Q2 2025, selling an estimated $816M.
  • Thomas Steyer's ten largest holdings make up 45% of its $23.8B portfolio in Q2 2025.
  • Thomas Steyer opened 18 new positions and closed 20 in Q2 2025.
  • Thomas Steyer's portfolio value rose 14% quarter-over-quarter to $23.8B.

Based on Farallon Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.